<p>無論您的投資風格如何，我們都希望能找到被忽視的股票寶石。這些地方是獲利最豐厚的地方。但是找到這些股票可能是一項挑戰。擁有投資者在 30 年前只能夢想到的信息是一把雙刃劍。很難區分隱藏的寶石和被炒作過度的垃圾股。</p>
<p>在這種時候，跟隨分析師的情緒可能會有所幫助。但是，根據定義，被忽視的股票是分析師要麼忽視的股票，要麼因為錯誤的原因而對其持負面態度。在本文中，我將關注那些在過去 60 天中被一個或多個分析師降級或調低目標價的股票。</p>
<p>分析師經常短視。在這個羣體中，買傳聞賣消息是很常見的。然而，如果您玩的是長期遊戲，並且有適當的風險承受能力，您可以找到像下面列出的這三隻被忽視的股票寶石。</p>
<h2>Pure Storage（PSTG）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>圖片來源：Tada Images / Shutterstock</p>
<p><strong>Pure Storage</strong>（紐約證券交易所：<strong>PSTG</strong>）可能看起來是被忽視的股票寶石名單中的一個奇怪選擇。PSTG 股價在過去 12 個月上漲了 73%，在 2024 年上漲了 81%。這使得該股更有可能被高估而不是低估。這也是分析師們似乎相信的。</p>
<p>該公司發佈了一份紮實的財報，年度收入和利潤均同比增長。但是，與 <strong>Palantir Technologies</strong>（紐約證券交易所：<strong>PLTR</strong>）類似，一些分析師認為增長不足以證明進一步的股價增長。在過去 30 天裏，<strong>摩根大通</strong>（紐約證券交易所：<strong>MS</strong>）和 <strong>瑞士銀行集團</strong>（紐約證券交易所：<strong>UBS</strong>）已經將該股降級，瑞士銀行集團甚至給予該股一個罕見的賣出評級。</p>
<p>人們認為 Pure Storage 將很難以足以證明其估值的激進速度增長。增加這一擔憂的是該公司所處的數據中心領域的競爭日益激烈。</p>
<p>儘管如此，分析師們普遍看好 PSTG 股票，並對其有比當前價格高 9% 的共識目標價。</p>
<h2>Paramount Global（PARA）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/uploads/2024/05/paramount-300x152.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/uploads/2024/05/paramount-300x152.png"/></p>
<p>當分析師以賣出評級開始覆蓋股票時，總是令人擔憂。然而，這正是發生在 <strong>Paramount Global</strong>（納斯達克證券交易所：<strong>PARA</strong>）身上的事。6 月 25 日，<strong>高盛</strong>（紐約證券交易所：<strong>GS</strong>）以賣出評級和 9.50 美元的目標價開始覆蓋 PARA 股票。這是在 <strong>富國銀行</strong>（紐約證券交易所：<strong>WFC</strong>）將 PARA 股票降級為低配並給予 9 美元的價格標籤之後。</p>
<p>圍繞 Paramount 的問題對於任何關注該股票的人都是眾所周知的。在正在發生的流媒體行業的強強對話中，該公司被留下了。它找不到買家。最公開的指責是隨着與其大股東 <strong>Skydance</strong> 合併的談判破裂。</p>
<p>但情況可能正在發生變化。PARA 股票在合併消息傳出後上漲。雖然仍有許多障礙需要克服，但如果 Paramount 在流媒體領域有一個可行的位置，它可能成為 2024 年被忽視的股票寶石之一。</p>
<h2>2seventy bio（TSVT）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>圖片來源：Matej Kastelic / Shutterstock</p>
<p>如果您正在尋找被忽視的股票寶石，那麼低價股是一個不錯的起點。這對於 <strong>2seventy bio</strong>（納斯達克證券交易所：<strong>TSVT</strong>）來説就是這種情況。這家細胞和基因療法公司市值僅為 2.06 億美元，但它有收入——這是許多同等規模公司無法聲稱的。</p>
<p>在這種情況下，該公司獲得了 Abecma 的 FDA 批准。這是一種用於晚期多發性骨髓瘤患者的細胞療法。該公司與 <strong>百時美施貴寶</strong>（紐約證券交易所：<strong>BMY</strong>）合作開發了這種療法。更重要的是，2seventy bio 最近獲得了 Abecma 的擴展標籤，可能會增加收入。</p>
<p>這對至少一位分析師來説還不足以安撫。6 月 6 日，高盛將 TSVT 股票的評級從中性調低為賣出，並設定了 2 美元的新目標價。即使 <strong>Wedbush</strong> 保持中性評級，分析師們也只給出 5 美元的目標價。</p>
<p>對於一家在利率仍然較高的時候沒有盈利的公司來説，這並不是獨特的。但是朝着盈利的持續進展以及利率下調可能足以使這些降級看起來過度。</p>
<p>_在發佈日期，Chris Markoch 持有 PLTR 的多頭頭寸。本文中表達的觀點屬於作者個人，遵守 InvestorPlace.com 的發佈準則。</p>
<p>_在發佈日期，負責編輯在本文提到的證券中沒有（直接或間接）任何頭寸。</p>
<p>Chris Markoch 是一名自由金融撰稿人，已經覆蓋市場超過五年。他自 2019 年以來一直為 InvestorPlace 撰寫文章。</p>

PSTG

派拉蒙環球

PARAA

TSVT

<p>華爾街忽視的 3 個潛力股：本文討論了分析師在過去 60 天內下調評級或降低目標股價的被忽視的潛力股。文章重點介紹了三家公司：Pure Storage（PSTG）、Paramount Global（PARA）和 2seventy bio（TSVT）。文章提供了關於分析師情緒以及下調評級背後的原因的信息，同時還探討了這些股票的潛在增長機會</p>

<p>No matter your investing style, we all hope to find overlooked stock gems. These are where the biggest gains are made. But finding these stocks can be a challenge. Having access to information investors could only have dreamt of 30 years ago is a double-edged sword. It can be difficult to distinguish between hidden gems and hyped-up junk.</p>
<div class="lb-trans"><p>無論您的投資風格如何，我們都希望能找到被忽視的股票寶石。這些地方是獲利最豐厚的地方。但是找到這些股票可能是一項挑戰。擁有投資者在 30 年前只能夢想到的信息是一把雙刃劍。很難區分隱藏的寶石和被炒作過度的垃圾股。</p>
</div><p>At times like these, it can be useful to follow analyst sentiment. But, by definition, overlooked stocks are stocks that either analysts ignore, or they’ve turned negative on for the wrong reason(s). For this article, I’m looking at stocks that one or more analysts have downgraded or lowered their price target in the last 60 days.</p>
<div class="lb-trans"><p>在這種時候，跟隨分析師的情緒可能會有所幫助。但是，根據定義，被忽視的股票是分析師要麼忽視的股票，要麼因為錯誤的原因而對其持負面態度。在本文中，我將關注那些在過去 60 天中被一個或多個分析師降級或調低目標價的股票。</p>
</div><p>Analysts frequently think short-term. Buying the rumor and selling the news is common among this group. However, if you play the long game and you have a suitable risk tolerance, you can find overlooked stock gems like the three listed below.</p>
<div class="lb-trans"><p>分析師經常短視。在這個羣體中，買傳聞賣消息是很常見的。然而，如果您玩的是長期遊戲，並且有適當的風險承受能力，您可以找到像下面列出的這三隻被忽視的股票寶石。</p>
</div><h2>Pure Storage (PSTG)</h2>
<div class="lb-trans"><h2>Pure Storage（PSTG）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: Tada Images / Shutterstock</p>
<div class="lb-trans"><p>圖片來源：Tada Images / Shutterstock</p>
</div><p><strong>Pure Storage</strong> (NYSE:<strong>PSTG</strong>) may seem to be an odd choice for a list of overlooked stock gems. The PSTG stock price is up 73% in the last 12 months and 81% in 2024. That would make the stock more likely to be overvalued than undervalued. And that’s what the analysts seem to believe.</p>
<div class="lb-trans"><p><strong>Pure Storage</strong>（紐約證券交易所：<strong>PSTG</strong>）可能看起來是被忽視的股票寶石名單中的一個奇怪選擇。PSTG 股價在過去 12 個月上漲了 73%，在 2024 年上漲了 81%。這使得該股更有可能被高估而不是低估。這也是分析師們似乎相信的。</p>
</div><p>The company reported a solid earnings report with year-over-year gains on the top and bottom lines. But, in a similar vein to <strong>Palantir Technologies</strong> (NYSE:<strong>PLTR</strong>), some analysts believe the growth is not enough to justify further stock price growth. In the last 30 days, <strong>Morgan Stanley</strong> (NYSE:<strong>MS</strong>) and <strong>UBS Group</strong> (NYSE:<strong>UBS</strong>) have downgraded the stock, with UBS giving the stock a rare Sell rating.</p>
<div class="lb-trans"><p>該公司發佈了一份紮實的財報，年度收入和利潤均同比增長。但是，與 <strong>Palantir Technologies</strong>（紐約證券交易所：<strong>PLTR</strong>）類似，一些分析師認為增長不足以證明進一步的股價增長。在過去 30 天裏，<strong>摩根大通</strong>（紐約證券交易所：<strong>MS</strong>）和 <strong>瑞士銀行集團</strong>（紐約證券交易所：<strong>UBS</strong>）已經將該股降級，瑞士銀行集團甚至給予該股一個罕見的賣出評級。</p>
</div><p>The belief is that Pure Storage will have a hard time growing at the aggressive pace needed to justify its valuation. Adding to that concern is the growing competition in the data center space that the company occupies.</p>
<div class="lb-trans"><p>人們認為 Pure Storage 將很難以足以證明其估值的激進速度增長。增加這一擔憂的是該公司所處的數據中心領域的競爭日益激烈。</p>
</div><p>Nevertheless, analysts are generally bullish on the PSTG stock and have a consensus price target of 9% higher than its current price.</p>
<div class="lb-trans"><p>儘管如此，分析師們普遍看好 PSTG 股票，並對其有比當前價格高 9% 的共識目標價。</p>
</div><h2>Paramount Global (PARA)</h2>
<div class="lb-trans"><h2>Paramount Global（PARA）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/uploads/2024/05/paramount-300x152.png" alt="" original-src="https://investorplace.com/wp-content/uploads/2024/05/paramount-300x152.png"/></p>
<p>It’s always cause for concern when analysts initiate their coverage with a Sell rating. However, that’s exactly what happened to <strong>Paramount Global</strong>(NASDAQ:<strong>PARA</strong>). On June 25, <strong>Goldman Sachs</strong>(NYSE:<strong>GS</strong>) initiated coverage on PARA stock with a Sell rating and a $9.50 price target. That comes after <strong>Wells Fargo</strong>(NYSE:<strong>WFC</strong>) downgraded PARA stock to Underweight and slapped a $9 price tag on the stock.</p>
<div class="lb-trans"><p>當分析師以賣出評級開始覆蓋股票時，總是令人擔憂。然而，這正是發生在 <strong>Paramount Global</strong>（納斯達克證券交易所：<strong>PARA</strong>）身上的事。6 月 25 日，<strong>高盛</strong>（紐約證券交易所：<strong>GS</strong>）以賣出評級和 9.50 美元的目標價開始覆蓋 PARA 股票。這是在 <strong>富國銀行</strong>（紐約證券交易所：<strong>WFC</strong>）將 PARA 股票降級為低配並給予 9 美元的價格標籤之後。</p>
</div><p>The issues surrounding Paramount are well-known to anyone following the stock. In the game of musical chairs that is happening in the streaming industry, the company is left without a chair. It can’t find a buyer. The most public rebuke came as talks of merging with its majority shareholder, <strong>Skydance</strong>, fell through.</p>
<div class="lb-trans"><p>圍繞 Paramount 的問題對於任何關注該股票的人都是眾所周知的。在正在發生的流媒體行業的強強對話中，該公司被留下了。它找不到買家。最公開的指責是隨着與其大股東 <strong>Skydance</strong> 合併的談判破裂。</p>
</div><p>But that may be changing. PARA stock is moving higher on news that the merger is back on. There are still many obstacles to clear, but if Paramount has a viable place in the streaming landscape, it may become one of the overlooked stock gems of 2024.</p>
<div class="lb-trans"><p>但情況可能正在發生變化。PARA 股票在合併消息傳出後上漲。雖然仍有許多障礙需要克服，但如果 Paramount 在流媒體領域有一個可行的位置，它可能成為 2024 年被忽視的股票寶石之一。</p>
</div><h2>2seventy bio (TSVT)</h2>
<div class="lb-trans"><h2>2seventy bio（TSVT）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: Matej Kastelic / Shutterstock</p>
<div class="lb-trans"><p>圖片來源：Matej Kastelic / Shutterstock</p>
</div><p>If you’re looking for overlooked stock gems, penny stocks are a good place to start. That’s the case for <strong>2seventy bio</strong> (NASDAQ:<strong>TSVT</strong>). The cell and gene therapy company has just a $206 million market cap, but it has revenue — which is something many companies its size cannot claim.</p>
<div class="lb-trans"><p>如果您正在尋找被忽視的股票寶石，那麼低價股是一個不錯的起點。這對於 <strong>2seventy bio</strong>（納斯達克證券交易所：<strong>TSVT</strong>）來説就是這種情況。這家細胞和基因療法公司市值僅為 2.06 億美元，但它有收入——這是許多同等規模公司無法聲稱的。</p>
</div><p>In this case, the company received FDA approval for Abecma. It’s a cellular therapy for advanced-stage multiple myeloma patients. The company developed the therapy as part of its collaboration with <strong>Bristol Myers Squibb</strong> (NYSE:<strong>BMY</strong>). Better still, 2seventy bio recently received an expanded label for Abecma that may increase revenue.</p>
<div class="lb-trans"><p>在這種情況下，該公司獲得了 Abecma 的 FDA 批准。這是一種用於晚期多發性骨髓瘤患者的細胞療法。該公司與 <strong>百時美施貴寶</strong>（紐約證券交易所：<strong>BMY</strong>）合作開發了這種療法。更重要的是，2seventy bio 最近獲得了 Abecma 的擴展標籤，可能會增加收入。</p>
</div><p>That hasn’t been enough to placate at least one analyst. On June 6, Goldman Sachs downgraded TSVT stock from a Neutral to a Sell with a new price target of $2. And even with <strong>Wedbush</strong> maintaining its Neutral rating, analysts only give the stock a $5 price target.</p>
<div class="lb-trans"><p>這對至少一位分析師來説還不足以安撫。6 月 6 日，高盛將 TSVT 股票的評級從中性調低為賣出，並設定了 2 美元的新目標價。即使 <strong>Wedbush</strong> 保持中性評級，分析師們也只給出 5 美元的目標價。</p>
</div><p>This isn’t unique for a company that is unprofitable at a time when interest rates remain high. But continued progress towards profitability combined with a rate cut may be enough to make these downgrades look overdone.</p>
<div class="lb-trans"><p>對於一家在利率仍然較高的時候沒有盈利的公司來説，這並不是獨特的。但是朝着盈利的持續進展以及利率下調可能足以使這些降級看起來過度。</p>
</div><p><em>On the date of publication, Chris Markoch had a long position in PLTR. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.</em></p>
<div class="lb-trans"><p>_在發佈日期，Chris Markoch 持有 PLTR 的多頭頭寸。本文中表達的觀點屬於作者個人，遵守 InvestorPlace.com 的發佈準則。</p>
</div><p><em>On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.</em></p>
<div class="lb-trans"><p>_在發佈日期，負責編輯在本文提到的證券中沒有（直接或間接）任何頭寸。</p>
</div><p>Chris Markoch is a freelance financial copywriter who has been covering the market for over five years. He has been writing for InvestorPlace since 2019.</p>
<div class="lb-trans"><p>Chris Markoch 是一名自由金融撰稿人，已經覆蓋市場超過五年。他自 2019 年以來一直為 InvestorPlace 撰寫文章。</p>
</div>

華爾街忽視的三隻隱藏股票瑰寶